Can Lifecycle Management Become Consumer Health’s Biggest Growth Lever?

Consumer Health companies hold some of their most valuable assets in established brands yet many still manage them through periodic launches, packaging updates and reactive line extensions. As consumer expectations evolve faster, the risk is not simply decline; it is allowing trusted brand equity, clinical heritage and established distribution to lose relevance.

Our experts explore how LifeCycle Management (LCM) can shift from a maintenance activity to a continuous, cross-functional growth engine. The focus is on helping leaders identify emerging consumer needs early, renew the value of existing assets and direct investment toward the brands, formats, channels and need states with the strongest potential to create profitable growth.

Key discussion takeaways

• Why legacy brands remain strategic assets and why inaction becomes riskier as expectations for efficacy, evidence, convenience, transparency and personalized care rise

• How need-state-led thinking can expand a brand beyond the product it is known for, without diluting the equity consumers trust

• The four LCM jobs that create value: improve the asset, extend relevance into new needs, expand access and strengthen growth quality through better mix, margin and portfolio discipline

• How continuous consumer, science, market and regulatory signals can reveal whitespace before value erodes

• Where leaders can unlock growth through reformulation, formats, premiumization, Rx-to-OTC pathways, channel expansion, digital discovery and selective portfolio rationalization

• Why successful LCM requires shared ownership across brand, R&D, commercial and portfolio teams

The discussion makes the case for a more disciplined model: continually scan, prioritize, codify and accelerate the next best growth move.